Application of bioactive peptide in inhibition of bone marrow toxicity

A bioactive peptide and bone marrow toxicity technology, applied in the field of medicine, can solve the problems of low immune function, peripheral blood cell reduction, high price, etc., and achieve the effects of significantly regulating immune function, significant antioxidant activity, and easy absorption

Pending Publication Date: 2022-01-21
河南省医药科学研究院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to its lack of specificity, it will also destroy normal cells while killing tumor cells, especially the damage to the vigorously proliferating bone marrow hematopoietic system, thereby inhibiting bone marrow hematopoiesis and resulting in decreased peripheral blood cells; Infection and other adverse reactions caused many tumor patients receiving chemotherapy to be forced to reduce or discontinue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0017] Example a: Albumin peptides and oligopeptides Inhibition Corn cisplatin (DDP) side effects of

[0018] 1. Experimental Animals

[0019] 6 to 8 week old SPF grade male C57BL / 6 mice were purchased from the Experimental Animal Center of Henan (Production License: SCXK (Yu) 2017-0001), for feeding to the Laboratory Animal Room liver pharmacologically Henan. After adaptive feeding and observed for 5 days for health active selected mice experiments.

[0020] 2. Experimental methods

[0021] 2.1 Grouping and administration

[0022] The 24 weighing 18 ~ 20g SPF level of C57BL / 6 mice were randomly divided into four groups, A: control group, B: DDP group, C: DDP + ovalbumin peptide group, D: DDP + Y corn oligopeptide Group. B, C, D group in daily 4mg / kg dosage by intraperitoneal injection DDP, 5 days, A group were intraperitoneally injected normal saline. After 1 hour, C, and D, respectively, and then 600mg / kg (0.2mL / 10g) and ovalbumin peptide gavage dose of corn oli

Example Embodiment

[0033] Example Two: Corn and ovalbumin peptide inhibition studies oligopeptides of doxorubicin-induced toxicity (of DOX)

[0034] 1. Experimental Animals

[0035] 6 to 8 week old SPF grade male C57BL / 6 mice were purchased from the Experimental Animal Center of Henan (Production License: SCXK (Yu) 2017-0001), for feeding to the Laboratory Animal Room liver pharmacologically Henan. After adaptive feeding and observed for 5 days for health active selected mice experiments.

[0036] 2. Experimental methods

[0037] 2.1 Grouping and administration

[0038] The 24 weighing 18 ~ 20g SPF level of C57BL / 6 mice were randomly divided into four groups, A: control group, B: DOX group, C: DOX + ovalbumin peptide group, D: DOX + Corn oligopeptide group . B, C, D group to 17mg / kg intraperitoneal dose of DOX, A group were intraperitoneally injected normal saline. After 1 hour, C, and D, respectively, and then 600mg / kg (0.2mL / 10g) and ovalbumin peptide gavage dose of corn oligopept

Example Embodiment

[0049] Example III: ovalbumin peptide inhibition studies and corn oligopeptides toxicity induced by daunorubicin (DNR)

[0050] 1. Experimental Animals

[0051] 6 to 8 week old SPF grade male C57BL / 6 mice were purchased from the Experimental Animal Center of Henan (Production License: SCXK (Yu) 2017-0001), for feeding to the Laboratory Animal Room liver pharmacologically Henan. After adaptive feeding and observed for 5 days for health active selected mice experiments.

[0052] 2. Experimental method

[0053] 2.1 Grouping and administration

[0054] SPF grade C57BL / 6 mice with 24 g weight of 18 to 22 g were randomly divided into 4 groups, A: Control group, B: Softxamicin (DNR) group, C: DNR + albin peptide group, D: DNR + Corn low polypeptide group. B, C, and D group injected DNR in a 1 mg / kg dose, a group of abdominal injection isometric normal saline. After 1 hour, C, D group were given a 600 mg / kg (0.2 ml / 10g) dose intravascular polyprotin peptide and corn oligope

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of a bioactive peptide in preparation of a medicine for inhibiting bone marrow toxicity. Wherein the bioactive peptide is albumin peptide or corn oligopeptide. The application of the bioactive peptide refers to the inhibition effect of the bioactive peptide on bone marrow toxicity caused by cis-platinum, adriamycin or daunorubicin. The bone marrow toxicity is hematopoietic function impairment, and is specifically represented by reduction of the number of peripheral blood leucocytes, and/or reduction of the number of peripheral blood erythrocytes, and/or reduction of the number of platelets. According to the invention, biological functions except oxidation resistance of the albumin peptide and the corn oligopeptide are found, and the application range of the bioactive peptide is expanded; and the bioactive peptide has a remarkable effect of inhibiting bone marrow toxicity and has no side effect.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner 河南省医药科学研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products